Search hospitals > California > Vacaville
Kaiser Permanente Medical Center-Vacaville
Claim this profileVacaville, California 95688
Global Leader in Thyroid Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
154 reported clinical trials
6 medical researchers
Summary
Kaiser Permanente Medical Center-Vacaville is a medical facility located in Vacaville, California. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Kaiser Permanente Medical Center-Vacaville is involved with conducting 154 clinical trials across 319 conditions. There are 6 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Natalya Greyz-Yusupov.Area of expertise
1Thyroid Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
PR positive
Top PIs
Jennifer M. SugaKaiser Permanente-Oakland1 year of reported clinical research
Expert in Non-Small Cell Lung Cancer
Expert in Lung Cancer
38 reported clinical trials
103 drugs studied
Samantha A. SeawardKaiser Permanente Medical Center - Santa Clara3 years of reported clinical research
Studies Breast Cancer
Studies Prostate Cancer
22 reported clinical trials
63 drugs studied
Tatjana Kolevska, MDKaiser Permanente-Vallejo2 years of reported clinical research
Studies Skin Cancer
Studies Cutaneous Melanoma
22 reported clinical trials
52 drugs studied
Natalya Greyz-YusupovKaiser Permanente-Fresno5 years of reported clinical research
Studies Breast Cancer
Studies Breast cancer
7 reported clinical trials
13 drugs studied
Clinical Trials running at Kaiser Permanente Medical Center-Vacaville
Lung Cancer
Breast Cancer
Ovarian Cancer
Skin Cancer
Non-Small Cell Lung Cancer
Prostate Cancer
Cutaneous Melanoma
Thyroid Cancer
Breast cancer
Squamous Cell Carcinoma
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Treatment Timing
for Non-Small Cell Lung Cancer
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patients with lung cancer. Treatment will be administered according to the current standard of care at the time of enrollment. Chemotherapy options may include cisplatin, carboplatin, pemetrexed, gemcitabine, docetaxel, and vinorelbine at standard doses according to the treating physician. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make deoxyribonucleic acid (DNA) and may kill tumor cells. Gemcitabine is a chemotherapy drug that blocks the cells from making DNA and may kill tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Other chemotherapy drugs, such as vinorelbine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading . Immunotherapy with monoclonal antibodies, such as nivolumab, pembrolizumab, and atezolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with chemotherapy and immunotherapy prior to surgery and continuing treatment after surgery may be a more effective treatment option than adjuvant therapy alone in patients with stage II-IIIB resectable NSCLC.
Recruiting2 awards Phase 34 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Kaiser Permanente Medical Center-Vacaville?
Kaiser Permanente Medical Center-Vacaville is a medical facility located in Vacaville, California. This center is recognized for care of Thyroid Cancer, Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Kaiser Permanente Medical Center-Vacaville is involved with conducting 154 clinical trials across 319 conditions. There are 6 research doctors associated with this hospital, such as Jennifer M. Suga, Samantha A. Seaward, Tatjana Kolevska, MD, and Natalya Greyz-Yusupov.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.